leadf
logo-loader
viewMedexus Pharmaceuticals Inc

Medexus says its joint-disease drug added to public drug plan in Quebec and will enjoy insurance coverage

The company said it is “looking forward” to advancing the commercial rollout of Triamcinolone Hexacetonide in additional provinces

Medexus Pharmaceuticals Inc - Medexus says its joint-disease drug added to public drug plan in Quebec and will enjoy insurance coverage
Medexus CEO Ken d’Entremont said the company will now be able to access a large group of children and adult patients suffering from "debilitating forms of joint disease"

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:PDDPF) announced Monday that its joint-disease drug Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been added to the public drug plan in Quebec.

The Toronto-based specialty pharmaceutical company said the drug has been approved for inclusion on the List of Medications-Basic Plan and the List of Medications-Institutions administered by the Régie de l’assurance maladie du Québec (RAMQ) from August 19.

According to the company, Quebec’s health technology assessment agency, or the Institut national d'excellence en santé et en services sociaux (INESSS) recommended that TH be included on the List of Medications covered by the basic prescription drug insurance plan, and the List of Medications – Institutions which includes hospitals with no restrictions on reimbursement.

READ: Medexus Pharmaceuticals sees record revenue during its fiscal 1Q thanks to solid sales of its drug portfolio

In a statement, Medexus CEO Ken d’Entremont said: “We are pleased about the addition of TH to the public drug plan formularies in Quebec and look forward to advancing the commercial rollout of TH in additional provinces across Canada over the coming months.”

He added: “With the inclusion of our TH on RAMQ’s List of Medications, we are able to access a large group of children and adult patients suffering from debilitating forms of joint disease, who previously could not get the product due to a long-standing shortage of TH in Canada.”

TH is the longest acting corticosteroid injection used to treat many different types of inflammatory conditions, often lasting twice as long as comparator products, the company said. 

“We believe TH will transform the treatment of many subacute and chronic inflammatory joint diseases as it provides a longer duration of action, with fewer injections, compared to other corticosteroid injections and intra-articular steroids,” added d’Entremont.

“By reducing the number of injections, TH offers a safer and more cost-effective solution, thereby reducing the number of hospital visits, which is particularly important in the current coronavirus (COVID-19) environment.”

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: Medexus Pharmaceuticals Inc

Price: 5.37 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $77.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Medexus Pharmaceuticals boosts 2Q revenue attributed to IXINITY acquisition

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) (FRA:P731) CEO Ken d’Entremont tells Proactive its second quarter revenue rose to C$23.6 million from C$16.4 million during the same period last year, which it attributed mainly to its acquisition of IXINITY, as well as solid performances from...

2 weeks, 2 days ago

2 min read